Literature DB >> 24762396

Transient induction of ING4 by Myc drives prostate epithelial cell differentiation and its disruption drives prostate tumorigenesis.

Penny L Berger1, Sander B Frank2, Veronique V Schulz1, Eric A Nollet2, Mathew J Edick1, Brittany Holly1, Ting-Tung A Chang1, Galen Hostetter1, Suwon Kim1, Cindy K Miranti3.   

Abstract

The mechanisms by which Myc overexpression or Pten loss promotes prostate cancer development are poorly understood. We identified the chromatin remodeling protein, ING4, as a crucial switch downstream of Myc and Pten that is required for human prostate epithelial differentiation. Myc-induced transient expression of ING4 is required for the differentiation of basal epithelial cells into luminal cells, while sustained ING4 expression induces apoptosis. ING4 expression is lost in >60% of human primary prostate tumors. ING4 or Pten loss prevents epithelial cell differentiation, which was necessary for tumorigenesis. Pten loss prevents differentiation by blocking ING4 expression, which is rescued by ING4 re-expression. Pten or ING4 loss generates tumor cells that co-express basal and luminal markers, indicating prostate oncogenesis occurs through disruption of an intermediate step in the prostate epithelial differentiation program. Thus, we identified a new epithelial cell differentiation switch involving Myc, Pten, and ING4, which when disrupted leads to prostate tumorigenesis. Myc overexpression and Pten loss are common genetic abnormalities in prostate cancer, whereas loss of the tumor suppressor ING4 has not been reported. This is the first demonstration that transient ING4 expression is absolutely required for epithelial differentiation, its expression is dependent on Myc and Pten, and it is lost in the majority of human prostate cancers. This is the first demonstration that loss of ING4, either directly or indirectly through loss of Pten, promotes Myc-driven oncogenesis by deregulating differentiation. The clinical implication is that Pten/ING4 negative and ING4-only negative tumors may reflect two distinct subtypes of prostate cancer. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24762396      PMCID: PMC4066454          DOI: 10.1158/0008-5472.CAN-13-3076

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  47 in total

1.  Inhibitor of growth-4 promotes IkappaB promoter activation to suppress NF-kappaB signaling and innate immunity.

Authors:  Andrew H Coles; Hugh Gannon; Anna Cerny; Evelyn Kurt-Jones; Stephen N Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

Review 2.  Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling?

Authors:  Ivan V Litvinov; Angelo M De Marzo; John T Isaacs
Journal:  J Clin Endocrinol Metab       Date:  2003-07       Impact factor: 5.958

3.  Silencing of thrombospondin-1 is critical for myc-induced metastatic phenotypes in medulloblastoma.

Authors:  Limei Zhou; Daniel Picard; Young-Shin Ra; Meihua Li; Paul A Northcott; Yaqi Hu; Duncan Stearns; Cynthia Hawkins; Michael D Taylor; James Rutka; Sandy D Der; Annie Huang
Journal:  Cancer Res       Date:  2010-09-28       Impact factor: 12.701

4.  Molecular classification of prostate cancer using curated expression signatures.

Authors:  Elke K Markert; Hideaki Mizuno; Alexei Vazquez; Arnold J Levine
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-28       Impact factor: 11.205

5.  Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor.

Authors:  G A Gmyrek; M Walburg; C P Webb; H M Yu; X You; E D Vaughan; G F Vande Woude; B S Knudsen
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

6.  Loss of heterozygosity at 12P12-13 in primary and metastatic prostate adenocarcinoma.

Authors:  A S Kibel; D A Faith; G S Bova; W B Isaacs
Journal:  J Urol       Date:  2000-07       Impact factor: 7.450

7.  Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells.

Authors:  Raanan Berger; Phillip G Febbo; Pradip K Majumder; Jean J Zhao; Shayan Mukherjee; Sabina Signoretti; K Thirza Campbell; William R Sellers; Thomas M Roberts; Massimo Loda; Todd R Golub; William C Hahn
Journal:  Cancer Res       Date:  2004-12-15       Impact factor: 12.701

8.  ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells.

Authors:  Yang Zong; Li Xin; Andrew S Goldstein; Devon A Lawson; Michael A Teitell; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-10       Impact factor: 11.205

9.  Loss of heterozygosity at 7q31.1 and 12p13-12 in advanced prostate cancer.

Authors:  Yoko Kawana; Tomohiko Ichikawa; Hiroyoshi Suzuki; Takeshi Ueda; Akira Komiya; Yayoi Ichikawa; Yuzo Furuya; Koichiro Akakura; Tatsuo Igarashi; Haruo Ito
Journal:  Prostate       Date:  2002-09-15       Impact factor: 4.104

10.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer.

Authors:  Shunyou Wang; Jing Gao; Qunying Lei; Nora Rozengurt; Colin Pritchard; Jing Jiao; George V Thomas; Gang Li; Pradip Roy-Burman; Peter S Nelson; Xin Liu; Hong Wu
Journal:  Cancer Cell       Date:  2003-09       Impact factor: 31.743

View more
  19 in total

1.  Human stroma and epithelium co-culture in a microfluidic model of a human prostate gland.

Authors:  L Jiang; F Ivich; S Tahsin; M Tran; S B Frank; C K Miranti; Y Zohar
Journal:  Biomicrofluidics       Date:  2019-11-20       Impact factor: 2.800

2.  Identification of the inhibitor of growth protein 4 (ING4) as a potential target in prostate cancer therapy.

Authors:  Aymen Shatnawi; Sridhar A Malkaram; Tamer Fandy; Efrosini Tsouko
Journal:  Mol Cell Biochem       Date:  2019-11-27       Impact factor: 3.396

3.  Effect of 7,12-Dimethylbenz(α)anthracene on the Expression of miR-330, miR-29a, miR-9-1, miR-9-3 and the mTORC1 Gene in CBA/Ca Mice.

Authors:  Andras Tomesz; Laszlo Szabo; Richard Molnar; Arpad Deutsch; Richard Darago; Domokos Mathe; Ferenc Budan; Nowrasteh Ghodratollah; Timea Varjas; Balazs Nemeth; Istvan Kiss
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

Review 4.  INGs are potential drug targets for cancer.

Authors:  Runyun Zhang; Jianhua Jin; Juanjuan Shi; Yongzhong Hou
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-20       Impact factor: 4.553

Review 5.  Inhibitor of growth-4 is a potential target for cancer therapy.

Authors:  Shuping Yuan; Jianhua Jin; Juanjuan Shi; Yongzhong Hou
Journal:  Tumour Biol       Date:  2016-01-23

Review 6.  The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistance.

Authors:  Jelani C Zarif; Cindy K Miranti
Journal:  Cell Signal       Date:  2016-01-29       Impact factor: 4.315

7.  Overexpression of Inhibitor of Growth 4 Enhances Radiosensitivity in Non-Small Cell Lung Cancer Cell Line SPC-A1.

Authors:  Xuan Pan; Rui Wang; Haibo Bian; Wei De; Ping Zhang; Chenchen Wei; Zhaoxia Wang
Journal:  Technol Cancer Res Treat       Date:  2016-07-04

8.  Aberrant CREB1 activation in prostate cancer disrupts normal prostate luminal cell differentiation.

Authors:  M J Watson; P L Berger; K Banerjee; S B Frank; L Tang; S S Ganguly; G Hostetter; M Winn; C K Miranti
Journal:  Oncogene       Date:  2021-04-12       Impact factor: 9.867

9.  Tumor suppressor ING4 inhibits estrogen receptor activity in breast cancer cells.

Authors:  Madeline M Keenen; Suwon Kim
Journal:  Breast Cancer (Dove Med Press)       Date:  2016-11-17

10.  ING4 expressing oncolytic vaccinia virus promotes anti-tumor efficiency and synergizes with gemcitabine in pancreatic cancer.

Authors:  Yinfang Wu; Xiaozhou Mou; Shibing Wang; Xing-E Liu; Xiaodong Sun
Journal:  Oncotarget       Date:  2017-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.